Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 2
Submit an article Journal homepage
1,552
Views
4
CrossRef citations to date
0
Altmetric
Original Articles

Analysis of the immunity effects after enhanced hepatitis B vaccination on patients with lymphoma

Wei-Huang ZhuangDepartment of Hematology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, China
&
Ya-Ping WangDepartment of Hematology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, ChinaCorrespondence[email protected]
Pages 357-363 | Received 05 May 2019, Accepted 17 Sep 2019, Published online: 15 Oct 2019

References

  • Nath A, Agarwal R, Malhotra P, et al. Prevalence of hepatitis B virus infection in non-Hodgkin lymphoma: a systematic review and meta-analysis. Intern Med J. 2010;40(9):633–641.
  • Wei-Ping L, Wen Z, Xiao-Pei W, et al. [An analysis of hepatitis B virus infection rate in 405 cases of non-Hodgkin lymphoma]. Zhonghua Xue Ye Xue Za Zhi. 2011;32(8):521–524. Chinese.
  • Engels EA, Cho ER, Jee SH. Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study. Lancet Oncol. 2010;11(9):827–834.
  • Cil T, Altintas A, Pasa S, et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy. Leuk Lymphoma. 2008;49(5):939–947.
  • Meral A, Sevinir B, Günay U. Efficacy of immunization against hepatitis B virus infection in children with cancer. Med Pediatr Oncol. 2000;35(1):47–51.
  • Cho Y, Yu SJ, Cho EJ, et al. High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin’s lymphoma. J Med Virol. 2016;88(6):1010–1017.
  • Matsubara T, Nishida T, Shimoda A, et al. The combination of anti-HBc and anti-HBs levels is a useful predictor of the development of chemotherapy-induced reactivation in lymphoma patients with resolved HBV infection. Oncol Lett. 2017;14(6):6543–6552.
  • Sarmati L, Andreoni M, Antonelli G, et al. Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation-a position paper. Clin Microbiol Infect. 2017;23(12):935–940.
  • Kusumoto S, Tanaka Y, Ueda R, et al. Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy. J Gastroenterol. 2011;46(1):9–16.
  • Fwu CW, Chien YC, You SL, et al. Hepatitis B virus infection and risk of intrahepatic cholangiocarcinoma and non-Hodgkin lymphoma: a cohort study of parous women in Taiwan. Hepatology. 2011;53(4):1217–1225.
  • Marcucci F, Mele A. Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities. Blood. 2011;117(6):1792–1798.
  • Niitsu N, Hagiwara Y, Tanae K, et al. Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy. J Clin Oncol. 2010;28(34):5097–5100.
  • Yang HC, Tsou HH, Pei SN, et al. Quantification of HBV core antibodies may help predict HBV reactivation in lymphoma patients with resolved HBV infection. J. Hepatol. 2018;08(2):69.
  • Emir S, Büyükpamuk M, Akyüz C, et al. The comparison of antibody response to different hepatitis b vaccines with and without pre-S2 antigen in children with cancer. Pediatr Hematol Oncol. 2002;19(4):227–233.
  • Chao-Shuang L, Shun-Qin W, Xiao Q. L, et al. Revaccination efficacy of different dosages of hepatitis B vaccine among adult non-and hyporesponders. Chin J Infect Dis. 2009;27(2):109–113.
  • Dotlic S, Vranic S, Jakovljevic G, et al. Neonatal hyperimmune T-cell reaction mimicking T-cell non-Hodgkin’s lymphoma following BCG and hepatitis B co-vaccination. Virchows Arch. 2012;461(5):601–605.
  • Ramesh M, Marwaha RK, Chawla YK, et al. Seroconversion after hepatitis B vaccination in children receiving cancer chemotherapy. Indian Pediatr. 2000;37(8):882–886.
  • Kurzrock R, Redman J, Cabanillas F, et al. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin’s disease and with B symptoms. Cancer Res. 1993;53(9):2118–2122.
  • Shimba A, Cui G, Tani-Ichi S, et al. Glucocorticoids drive diurnal oscillations in T cell distribution and responses by inducing interleukin-7 receptor and CXCR4. Immunity. 2018;48(2):286–298.
  • Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med. 2001;344(1):68–69.
  • Tam CS, Anderson MA, Pott C, et al. Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma. N Engl J Med. 2018;378(13):1211–1223.
  • Sarantopoulos S. Allogeneic stem-cell transplantation – a T-cell balancing ACT. N Engl J Med. 2018;378(5):480–482.
  • Anderson KC. Lenalidomide and thalidomide: mechanisms of action–similarities and differences. Semin Hematol. 2005;42(4):S3–S8.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.